Last reviewed 2026-05-29 · How we verify

SL650472, Clopidogrel

Sanofi · Phase 2 active Small molecule ✓ Verified May 2026

SL650472, Clopidogrel is a Small molecule drug developed by Sanofi. It is currently in Phase 2 development.

SL650472 is a small molecule that is being studied as a potential treatment for intermittent claudication. It is a mixed antagonist of serotonin, and its efficacy is being compared to clopidogrel and cilostazol in a clinical trial.

Likelihood of approval

18.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Big-pharma sponsor +3.0pp
Sanofi is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	SL650472, Clopidogrel
Sponsor	Sanofi
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Mixed Antagonist of Serotonin for Claudication Optimal Therapy (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

SL650472, Clopidogrel CI brief — competitive landscape report
SL650472, Clopidogrel updates RSS · CI watch RSS
Sanofi portfolio CI

Frequently asked questions about SL650472, Clopidogrel

What is SL650472, Clopidogrel?

SL650472, Clopidogrel is a Small molecule drug developed by Sanofi.

Who makes SL650472, Clopidogrel?

SL650472, Clopidogrel is developed by Sanofi (see full Sanofi pipeline at /company/sanofi).

What development phase is SL650472, Clopidogrel in?

SL650472, Clopidogrel is in Phase 2.

Manufacturer: Sanofi — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing